Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
- No funding until mid 24
- Global Frontier Partners increased stake a few weeks back by ~2% last month
- Massive moat, no direct competition with FDA approval
- Ovarian cancer study delivering best in class results, far out-performing standard of care for the detection of ovarian cancer demonstrating the value of the Parsortix® system in the real-world
- Progressing with Prostate cancer studies utilising the Parsortix system in collaboration with Solaris Health Holdings. Studies expected to complete 2023 with Solaris marketing a Parsortix prostate cancer test to its patient base of over 729,000 patients annually.
- Strong position to play a leading role in emerging US$ 100 billion dollar liquid biopsy market for personalised cancer care
- 2 heavy weight hitters joined the team AGL and now has the resources in place to deliver on its strategic and commercial plans
- Pipeline of global opportunities growing strongly, engagement with major pharma companies, medtech companies and clinical laboratories.
The list goes on.....Feels like a fair risk reward trade of these levels
Trinity Delta report March 2023
https://twitter.com/aim_gravy/status/1643145040041070593
Looks to be a key resistance point here, having tested a few times in the last week. Once we break through £1.50 we should get to a min of £1.60-65 prior to results...IF the market holds up
Either way, BARC are cheap even with a US recession looming, UK doing ok. The beauty of a diversified banking business
Try reading the last RNS as a guide....
Staylock - Dont read to much into recorded buys/sells. All buys and sells are matched on large/med cap shares (via order matching systems).
In simple terms you could see 100% buys, but on the other side you get sells. As a rule, shares rise and fall based on the underlying demand, not necessarily the number of buys Vs sells you see recorded.
However, if you trade small caps/AIM (these can sit outside of the order matching system) and are controlled in the main by market makers, other dynamic altogether. The job of the market maker is to make the market (ie keep it liquid) This can make SP more volatile where buys and sells dont necessarily need to be matched. But this is a topic in its own right
Hope that helps a little
Solid as usual, no surprises. I'm ok with divi level
What is disappointing is the amount of time it is taking to find acquisition. Think they have had same amount of site visits for the last 5 yrs. I truly think an acquisition is a 4th priority after production, H&S, Environment and Sustainability
Agree, comms have always been weak. Along with commercial strategy
Shame they did not put as much effort on the commercial side, as they did getting the FDA. Build it and they will come approach did not work....
First glimmer of light should see this bounce, as everyone gets all excited again
to the next hot topic. Banking crisis done.... All the pundits, journos, press have had their fill. Not to mention the few who have made a fortune off the back of "all banks are going to implode" and the US gov is plotting to bring crypto in through the back door (love a good conspiracy theory) Anyway, like wilder beast its time to start migrating to the next rich pasture ......and around we go...Hmmmm, commercial property, now theres a thought
Any thoughts on the impact on L&G.
Stateside, they reckon this is the next domino to fall, as commercial asset prices start to tumble.
Could be a reason for L&G SP under performance and may hit banks again. Although bank weightings are only ~ 6-8%. Not sure what exposure L&G have, but may be significant
Looking at CJs Mcap ~$126M , $rev etc, reckon they paid peanuts. Could be wrong, but unlikely